top of page
Browse by category
Search
SURMOUNT-3: Tirzepatide shows total mean weight loss of 26.6% from study entry over 84 weeks
Detailed results from the phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with...
Tirzepatide more effective in blood sugar control and body weight loss than semaglutide
A new meta-analysis combining 22 studies shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms...
NICE needs more evidence before recommending tirzepatide for T2DM treatment
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended tirzepatide (Mounjaro, developed by Eli Lilly) in...
Journal Watch 28/06/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Tirzepatide has unique ability to stimulate insulin secretion
Tirzepatide (Mounjaro) has a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy...
SURMOUNT-2: Tirzepatide achieved up to 15.7% weight loss
Seventy-two week outcomes from the SURMOUNT-2 trial has revealed that tirzepatide (10mg and 15mg) achieved superior weight loss compared...
SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs
Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro)...
Anti-obesity medications remain prohibitively expensive
Several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to...
SURPASS-4 trial: Tirzepatide slows rate of eGFR decline and reduces UACR in T2DM patients
An analysis of the SURPASS-4 trial has reported that type 2 diabetics with high cardiovascular risk who took resulted in a slowed the...
Browse by tag
bottom of page